Tillkännagivande • May 26
Virbac SA, Annual General Meeting, Jun 29, 2026 Virbac SA, Annual General Meeting, Jun 29, 2026. Location: 13e rue lid, carros France Tillkännagivande • Mar 18
Virbac Sa Proposes Dividend for the Fiscal Year 2025 Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year. Tillkännagivande • Jan 20
Virbac SA Provides Earnings Guidance for the Year 2026 Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope. Tillkännagivande • Dec 17
Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million. Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million on December 16, 2025. The transaction is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac.
Thyronorm has in-market sales of approximately €27 million.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Thyronorm from Norbrook Laboratories Limited on December 16, 2025. Tillkännagivande • Dec 08
Virbac SA to Report First Half, 2026 Results on Sep 17, 2026 Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026 Tillkännagivande • Oct 17
Virbac SA Updates Revenue Guidance for the Year 2025 Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before). Tillkännagivande • Sep 13
Virbac Sa Confirms Earnings Guidance for the Year 2025 Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025. Tillkännagivande • Jun 21
Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025 Virbac SA announced the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25
years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young, then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's
Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance. Tillkännagivande • May 13
Virbac SA, Annual General Meeting, Jun 19, 2025 Virbac SA, Annual General Meeting, Jun 19, 2025. Location: 13e rue lid, carros France Tillkännagivande • Jan 17
Virbac SA Provides Revenue Guidance for the Year 2025 Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%. Tillkännagivande • Dec 04
Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024. Tillkännagivande • Jul 17
Virbac SA Revises Earnings Guidance for the Fiscal Year 2024 Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%. Tillkännagivande • Jul 08
Virbac Sa Announces Chief Executive Officer Changes Virbac SA announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. About Habib Ramdani: Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020. Tillkännagivande • Apr 03
Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591). Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor.
Virbac SA (ENXTPA:VIRP) completed the acquisition of Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) on April 1, 2024. Tillkännagivande • Mar 08
Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million. Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor. Tillkännagivande • Jan 18
Virbac SA Provides Earnings Guidance for the Year 2024 Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023. Tillkännagivande • Sep 29
Virbac SA Confirms Revenue Forecasts for the Year 2023 Virbac SA confirmed revised revenue forecasts for the year 2023. The company confirms revised forecasts with revenue growth at constant rates and scope expected in a range between 0% and 4%. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €279, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €387 per share. Tillkännagivande • Dec 15
Virbac SA to Report First Half, 2023 Results on Sep 14, 2023 Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023 Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment deteriorated over the past week After last week's 22% share price decline to €275, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 32% over the past three years. Reported Earnings • Sep 21
First half 2022 earnings released: EPS: €9.18 (vs €8.54 in 1H 2021) First half 2022 results: EPS: €9.18 (up from €8.54 in 1H 2021). Revenue: €616.4m (up 16% from 1H 2021). Net income: €77.5m (up 7.7% from 1H 2021). Profit margin: 13% (down from 14% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 02
Full year 2021 earnings released: EPS: €13.40 (vs €16.13 in FY 2020) Full year 2021 results: EPS: €13.40 (down from €16.13 in FY 2020). Revenue: €1.06b (up 14% from FY 2020). Net income: €113.2m (down 17% from FY 2020). Profit margin: 11% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.9%, compared to a 5.3% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jun 16
Upcoming dividend of €0.75 per share Eligible shareholders must have bought the stock before 23 June 2021. Payment date: 25 June 2021. Trailing yield: 0.3%. Lower than top quartile of British dividend payers (4.0%). Lower than average of industry peers (3.6%). Reported Earnings • Mar 19
Full year 2020 earnings released: EPS €16.29 (vs €6.11 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €934.2m (flat on FY 2019). Net income: €137.5m (up 167% from FY 2019). Profit margin: 15% (up from 5.5% in FY 2019). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 26
New 90-day low: €202 The company is down 6.0% from its price of €216 on 27 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €205 per share. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €205, the stock is trading at a trailing P/E ratio of 25x, down from the previous P/E ratio of 30x. This compares to an average P/E of 18x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders over the past three years are 72%. Is New 90 Day High Low • Jan 05
New 90-day high: €246 The company is up 22% from its price of €202 on 07 October 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €225 per share. Is New 90 Day High Low • Dec 14
New 90-day high: €233 The company is up 26% from its price of €184 on 15 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €233 per share. 